Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory FRI study of extrafine CHF5993 pMDI in COPD
2017-000438-79Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Specific image-based airway volumes (siVaw). Started Jul 2017; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-000438-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000438-79.